InsiderTrades.com logo
A Simple Trading Strategy You Should Know
From DTI   |   Ad
It’s no secret, I love big, juicy options trades. But when you’re chasing the BIG fish, you gotta have a way to target some steady, consistent returns in there as well. Check out the $100 Challenge This Chris Pulver, he’s isolated a way for everyday folks to target $100-$150 a day in the stock market, starting with just $1,000 or so. And while we cannot promise future returns or against losses, It’s the perfect supplement to more aggressive options strategies… And right now, everyone needs more cash in this economy.
So sign up for the $100 Challenge here
Ludwig Hantson net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Ludwig Hantson Biography and Net Worth

CEO & Director of Alexion Pharmaceuticals
Dr. Ludwig N. Hantson Ph.D. serves as Chief Executive Officer, Director of the Company. Dr. Hantson became Chief Executive Officer of Alexion on March 27, 2017. Prior to joining Alexion, Dr. Hantson was President and Chief Executive Officer of Baxalta Incorporated. He led Baxalta’s successful spin-off as a public company from Baxter International Inc. in July 2015 where he was President of Baxter BioScience. He joined Baxter in May 2010 and established the BioScience division as an innovative specialty and rare disease company with a pipeline of 25 new product candidates, and 13 product launches. Prior to Baxter, from 2001 to 2010, Dr. Hantson held several leadership roles at Novartis AG, including CEO of Pharma North America, CEO of Europe, and President of Pharma Canada. Prior to Novartis, Dr. Hantson spent 13 years with Johnson & Johnson in roles of increasing responsibility in marketing and research and development. Dr. Hantson received his Ph.D. in motor rehabilitation and physical therapy, Master’s degree in physical education, and a certification in high secondary education, all from the University of Louvain in Belgium.

What is Ludwig Hantson's net worth?

The estimated net worth of Ludwig Hantson is at least $27.50 million as of December 31st, 2018. Dr. Hantson owns 150,696 shares of Alexion Pharmaceuticals stock worth more than $27,502,020 as of December 23rd. This net worth estimate does not reflect any other assets that Dr. Hantson may own. Additionally, Dr. Hantson receives a salary of $4,250,000.00 as CEO & Director at Alexion Pharmaceuticals. Learn More about Ludwig Hantson's net worth.

How old is Ludwig Hantson?

Dr. Hantson is currently 58 years old. There are 5 older executives and no younger executives at Alexion Pharmaceuticals. Learn More on Ludwig Hantson's age.

What is Ludwig Hantson's salary?

As the CEO & Director of Alexion Pharmaceuticals, Inc., Dr. Hantson earns $4,250,000.00 per year. Learn More on Ludwig Hantson's salary.

How do I contact Ludwig Hantson?

The corporate mailing address for Dr. Hantson and other Alexion Pharmaceuticals executives is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. Alexion Pharmaceuticals can also be reached via phone at 475-230-2596 and via email at [email protected]. Learn More on Ludwig Hantson's contact information.

Has Ludwig Hantson been buying or selling shares of Alexion Pharmaceuticals?

Ludwig Hantson has not been actively trading shares of Alexion Pharmaceuticals during the past quarter. Most recently, Ludwig Hantson sold 3,244 shares of the business's stock in a transaction on Monday, December 31st. The shares were sold at an average price of $95.85, for a transaction totalling $310,937.40. Learn More on Ludwig Hantson's trading history.

Who are Alexion Pharmaceuticals' active insiders?

Alexion Pharmaceuticals' insider roster includes Daniel Bazarko (CAO), Tanisha Carino (CAO), Paul Clancy (CFO), Indrani Franchini (EVP), Ludwig Hantson (CEO & Director), John Orloff (EVP), Vikas Sinha (CFO), and Heidi Wagner (SVP). Learn More on Alexion Pharmaceuticals' active insiders.

Ludwig Hantson Insider Trading History at Alexion Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/31/2018Sell3,244$95.85$310,937.40View SEC Filing Icon  
12/31/2018Sell3,244$95.85$310,937.40150,696View SEC Filing Icon  
2/8/2018Sell13,245$116.31$1,540,525.95131,425View SEC Filing Icon  
1/2/2018Sell2,553$121.63$310,521.3936,172View SEC Filing Icon  
6/14/2017Buy10,000$116.72$1,167,200.0038,725View SEC Filing Icon  
See Full Table

Ludwig Hantson Buying and Selling Activity at Alexion Pharmaceuticals

This chart shows Ludwig Hantson's buying and selling at Alexion Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alexion Pharmaceuticals Company Overview

Alexion Pharmaceuticals logo
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $182.50
Low: $182.50
High: $182.50

50 Day Range

MA: $182.82
Low: $179.45
High: $186.61

2 Week Range

Now: $182.50
Low: $99.91
High: $187.45

Volume

10 shs

Average Volume

3,309,941 shs

Market Capitalization

$40.34 billion

P/E Ratio

59.64

Dividend Yield

N/A

Beta

1.25
A Simple Trading Strategy You Should Know
From DTI   |   Ad
It’s no secret, I love big, juicy options trades. But when you’re chasing the BIG fish, you gotta have a way to target some steady, consistent returns in there as well. Check out the $100 Challenge This Chris Pulver, he’s isolated a way for everyday folks to target $100-$150 a day in the stock market, starting with just $1,000 or so. And while we cannot promise future returns or against losses, It’s the perfect supplement to more aggressive options strategies… And right now, everyone needs more cash in this economy.
So sign up for the $100 Challenge here